Navigation Links
GeneNews to conduct joint project funded by MYR 5 million grant from Malaysian government
Date:4/29/2009

    - Malaysian Ministry of Health provides grant to develop blood-based
    diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal
    cancer -

TORONTO, April 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will undertake a two-year joint project to develop blood-based diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal cancer based on their Sentinel Principle(TM) platform technology. The Malaysian Ministry of Health will provide a grant of MYR 5 million to support this work which will be executed by GeneNews (Malaysia) Sdn. Bhd., a subsidiary of GeneNews. Project funding was jointly announced by the Honourable Minister of Health for Malaysia Dato' Sri Liow Tiong Lai and the Director General of Health for Malaysia Tan Sri Datuk Dr. Haji Mohd Ismail Merican.

"Liver cancer, Hepatitis B - a liver disease that can result in liver cancer, and nasopharyngeal cancer - a cancer of the upper throat and nasal passages, are among the most significant causes of chronic disease and death in Asia," said Dr. C. C. Liew, Co-Founder and Chief Scientist of GeneNews. "Our project with the Malaysian Ministry of Health aims to develop blood-based, genomic diagnostic tests for the early detection and staging of these three diseases. This collaboration also gives GeneNews the opportunity to train select Malaysian Ministry of Health staff, contributing to their human capital development, and also adding depth to GeneNews' research and development expertise in Malaysia."

"In line with the strategic restructuring of our operations that was implemented last November, this research and development collaboration will allow us to develop additional tests based on our proprietary Sentinel Principle(TM) platform technology," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This joint project will benefit both the Malaysian government, which could drastically reduce the incidence of and health care expenses associated with these diseases, and GeneNews, through the expansion of our pipeline while we continue to focus on the North American and European commercialization of our ColonSentry(TM) test from our corporate headquarters in Canada."

    About GeneNews
    --------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry(TM), a blood-based test to assess an individual's risk for colorectal cancer, in Canada in 2008. For more information on GeneNews and ColonSentry(TM), visit www.genenews.com or www.colonsentry.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. GeneNews announces management changes to support commercialization of ColonSentry(TM)
11. GeneNews launches worlds first blood test for colorectal cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
(Date:2/21/2017)... ... 21, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... team to lead the development and commercialization of its Cancer Information Data Trust ... and treatment of cancer. The CIDT addresses the need for curated and structured ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
Breaking Biology Technology:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):